AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04414033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bubble: A New VR-AI Way of Treatment for Hot Flashes
Description: Bubble Bubble is a virtual reality (VR) mobile application. Bubble offers a psychological intervention based upon cognitive behavioral therapy (CBT) and mindfulness-based stress reduction (MBSR) protocols. The bubble mobile application offers the intervention in a virtual reality (VR) coaching environment and in a winter wonderland setting called Frosty. Frosty provides both a virtual reality winter wonderland experience as well as guided meditation. The cold, winter-like experience is designed to help patients calm down and feel cooler.
Study NCT02419833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate invasive intervention
Description: Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
Study NCT02419833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed invasive intervention
Description: Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and/or within 2-72 hours of admission
Study NCT02419833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery stenting
Description: Implantation of coronary stents
Study NCT02419833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary artery stenting
Description: Implantation of coronary stents
Study NCT03543709 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fibromyalgia 2013 criteria
Description: Frequency of fibromyalgia will be investigated in women diagnosed with Behcet disease
Study NCT03543709 — intervention group
Intervention type: OTHER
Intervention: Behcet's disease current activity form
Description: Disease activity will be investigated in women with Behçet's disease without fibromyalgia.
Study NCT02367625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoPop
Description: The new CryoPop device will be compared to standard cryotherapy
Study NCT02367625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedGyn MGC 200
Description: Standard cryotherapy
Study NCT00754494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT00754494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given PO
Study NCT00754494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03356106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: A non-invasive positive pressure device that is used for the treatment of obstructive sleep apnea by splinting the collapsed upper airway during sleep
Study NCT01734135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Reminder
Description: A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
Study NCT00756743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules q12 hours for 10 days
Study NCT02774538 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Agreement between oral and cervical HPV infection
Description: A total of 165 women will have a Pap test and an oral brushing performed on the day of inclusion. Risk factors for oral HPV infection will be defined using a self-administered survey summarizing the demographics and sexual behaviors.~A second oral brushing up to 18 months will be performed during a standard follow-up visit.
Study NCT00764413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: 1 gram intravenous a day for 3 days
Study NCT00764413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chlorid
Description: Sodium chlorid 9mg/ml 500 ml per day in 3 days
Study NCT00817817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MF
Description: One evening dose of dry powder inhaled MF 400 μg (Multidose device).
Study NCT02244515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
Study NCT01526200 — intervention group
Intervention type: PROCEDURE
Intervention: Contrast-enhanced intraoperative ultrasound
Description: After entering the abdominal cavity, liver mobilization is achieved by dissecting the round and falciform ligaments. IOUS is carried out with a standard 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging was completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist.
Study NCT00648414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1
Description: blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected
Study NCT00648414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2
Description: tourniquet applied just below patch application site and above blood draw site, while samples collected
Study NCT00648414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3
Description: tourniquet applied just above patch application site, while samples collected
Study NCT00648414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic 25 mcg/h + Clinical Procedure 1
Description: blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
Study NCT00648414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic 25 mcg/h + Clinical Procedure 2
Description: tourniquet applied just below patch application site and above blood draw site, while samples collected
Study NCT00648414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic 25 mcg/h + Clinical Procedure 3
Description: tourniquet applied just above patch application site, while samples collected
Study NCT00176748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG 6013736
Description: 5 mg po bid
Study NCT00509288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor
Description: Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes.~A minimum of approximately 5 X 10\^8 cells will be given up to 3x10\^11 anti-MART-1 F5 TCR engineered TIL or PBL.
Study NCT00509288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Study NCT03516019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekend notices
Description: notifications sent on Saturday
Study NCT00509288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -5 to 1: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days
Study NCT00509288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e\^11 (with a minimum of 5x10e\^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion
Study NCT00509288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes
Study NCT03795142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGB149
Description: Single Ascending Dose
Study NCT03795142 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03268564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIVST-online promotion
Description: Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~1. Viewing a promotion video and a demonstration video~2. Brief motivational interviewing through telephone~3. Visiting the HIVST-online webpage~4. Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~1. Viewing a promotion video and a demonstration video~2. Visiting the HIVST-online webpage~3. Receiving a free self-testing kit and follow-up reminders
Study NCT02009787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3 tablets
Description: 2000 IU vitamin D3 tablets were taken daily for 6 months
Study NCT02009787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: 2000 IU placebo tablets were taken daily for 6 months
Study NCT01784302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins
Study NCT01784302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Study NCT01784302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maalox Plus extra
Study NCT01784302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir 400 mg
Study NCT04380142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: Solution for continuous subcutaneous infusion (CSCI)
Study NCT04380142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Levodopa/Carbidopa (LD/CD)
Description: Oral capsule
Study NCT04380142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa/Carbidopa (LD/CD)
Description: Oral encapsulated tablet
Study NCT04380142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for ABBV-951
Description: Solution for continuous subcutaneous infusion (CSCI)
Study NCT00538850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray
Description: In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
Study NCT00538850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to fentanyl sublingual spray.
Study NCT01951391 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Hand Soap
Description: Commercially available soap will be used to wash the subject's forearms
Study NCT01951391 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Benzalkonium Chloride Soap
Description: Commercially available soap containing benzalkonium chloride will be used to wash the subject's forearms
Study NCT01951391 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Triclocarban Soap
Description: Commercially available soap containing triclocarban will be used to wash the subject's forearms
Study NCT03208673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optive® Fusion + Optive® Gel Drop
Description: Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.
Study NCT02333448 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample taken on the day the treatment is initiated
Study NCT02333448 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample taken on day 3 after initiation of treatment
Study NCT02333448 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample taken on day 5 after initiation of
Study NCT02333448 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample taken on day 7 after initiation of treatment
Study NCT02333448 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample taken on day 10 after initiation of treatment
Study NCT00265798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Study NCT00574015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocodone/acetaminophen
Description: oral hydrocodone 10 mg/acetaminophen 650 mg
Study NCT00574015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine (supraperiosteal nerve block)
Description: Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
Study NCT01389687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactive Poliovirus Vaccine
Description: 0.5 mL, Subcutaneous
Study NCT01533545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine with epinephrine
Description: Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
Study NCT01533545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain mepivacaine
Description: Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)
Study NCT02010502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Study NCT02010502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot powder
Study NCT02010502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01959932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS 2.2)
Description: THS 2.2 ad libitum for 5 days in confinement
Study NCT01959932 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Smoking abstinence (SA)
Description: SA for 5 days in confinement
Study NCT01959932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cigarette (CC)
Description: Subject's own preferred brand of CC ad libitum for 5 days in confinement
Study NCT04025554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg daily weeks 1-4, 200 mg daily weeks 5-8, 300 mg daily weeks 9-12.
Study NCT00749346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L
Description: TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
Study NCT03837509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with daratumumab SC.
Study NCT03837509 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab SC
Description: Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks. Daratumumab will be administered either as monotherapy or in combination with INCB001158.
Study NCT03837509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab SC
Description: Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks. Daratumumab will be administered either as monotherapy or in combination with INCB001158.
Study NCT00963872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 50 mg/kg intravenously (IV) over 2 hours on Day -6.
Study NCT00963872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 40 mg/m\^2 over 1 hour on Days -6 through -2.
Study NCT00963872 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy on Day -1
Study NCT00817817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MF
Description: One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
Study NCT03259919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg x 1 per day for the first week, and 850 mg x 2 per day for the rest of the study period.. Orally. From inclusion (before gestational week 8) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
Study NCT03259919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
Study NCT00963872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood unit with C3a fragment
Description: On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
Study NCT00963872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unmanipulated UCB Unit
Description: On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
Study NCT02115087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided rectus sheath block
Description: the application of rectus sheath block with ultrasound guidance
Study NCT02115087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT03949517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga RM2
Description: Radioactive agent
Study NCT03949517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga PSMA11
Description: Radioactive agent
Study NCT03949517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational software and coils in PET/MR Scan
Description: Investigational software and coils in PET/MR Scan by General Electric Healthcare
Study NCT03949517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: Positron emission tomography (PET)/Magnetic resonance imaging (MRI) Scan
Study NCT00561990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab
Study NCT00561990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nimotuzumab
Study NCT01777477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Addition of Chloroquine to Gemcitabine
Study NCT01777477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02916485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold
Description: Percutaneous coronary intervention (PCI)
Study NCT00485173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate
Description: All patients enrolled in this study will receive the investigational device.
Study NCT04193735 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans after a liquid meal
Description: Participants will be scanned fasted, then receive a liquid meal, then be scanned every half hour, seven times
Study NCT01915641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
Study NCT01915641 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPAP
Description: Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement